阎水忠博士于2015年9月加入再鼎医药，目前担任再鼎医药全球研发首席运营官。

加入再鼎之前，阎水忠博士是科文斯公司早期研发上海研发中心负责人，全面负责公司在中国的相关业务。2009年至2012年期间，阎水忠博士是和记黄埔医药公司药物安全性评价和项目管理负责人。加入和记黄埔医药之前，阎水忠博士在美国辉瑞积累了丰富的经验。在其职业生涯中，阎水忠博士参与过多个候选药物的IND和NDA申请工作，积累起与数个国家的卫生注册机构合作的丰富经验。

阎水忠博士拥有北京协和医科大学博士学位，并在美国芝加哥大学Ben-May癌症研究所完成博士后研究。阎水忠博士是美国毒理学会认证专家、中国毒理协会理事会理事、药物毒理与安全性评价专业委员会委员、中国药理学会药物毒理专业委员会委员及中国医药创新促进会药物研发专业委员会副主任委员。

    James Yan, Ph.D., joined Zai Lab in September 2015 and currently serves as Chief Operating Officer, Global R&D.

Prior to joining Zai Lab, Dr. Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2012, Dr. Yan served as the head of drug safety evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr. Yan was involved in many IND and NDA filings for multiple drug candidates and gained substantial experience working with regulatory agencies in several countries.

Dr. Yan holds a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago’s Ben-May Institute for Cancer Research. He is a diplomat of the American Board of Toxicology (DABT), a council member of the China Society of Toxicology and a member of the Drug Toxicity and Drug Safety Evaluation Committee, a member of Pharmaceutical Toxicology Committee of China Pharmacology Society and vice chairman of Drug R&D Committee of China Pharmaceutical Innovation and Research Association (PhIRDA).